Skip to main content
Division of Endocrinology & Metabolism Endocrinology & Metabolism

Majithia Lab

About the Lab

Insulin resistance causes the epidemic diseases of our era...but it is invisible even to trained clinical eyes.

The Majithia Lab applies the tools of functional genomics, bioinformatics, and human genetics in a collaborative, multi-disciplinary research environment. We participate in several research centers including the UCSD-UCLA Diabetes Research Center, Altman Clinical and Translational Research Institute, and the Institute for Genomic Medicine as well as the Center for Engineering in Diabetes (CED) in the Institute of Engineering in Medicine.

Our Mission

Develop new ways to detect and treat insulin resistance.

About Our Mission

Our Approach

Genotype-Function-Phenotype

We apply a multi-disciplinary approach to investigation — grounded in human genetics, clarified through systematic, high throughput cellular experimentation, and calibrated by its relevance to disease.

  1. Genotype: human genetic/genomic variation; genome engineering
  2. Function: massively parallel, disease-calibrated cellular assays; serum/tissue biomarkers
  3. Phenotype: clinical trial outcomes and real-world patient health data

Our Research Programs

Therapeutic Target Identification

Identify genes that protect from insulin resistance

Individually Tailored Therapy

Massively parallel assay to predict drug response

Next-generation Phenotyping

Distinguishing the many diseases that are called type 2 diabetes

Join Our Team

The Majithia Lab is recruiting talented and enthusiastic scientists at all levels to join our group!

Available Positions

Lab News & Announcements

  • February 2025: Welcome Postdoctoral Researcher Kavita Koshta! Kavita brings expertise in adipocyte biology and mouse models of metabolism.
  • January 2025: Our work to characterize an alternatively translated isoform of PPARG and the effect on its activity has been published in Diabetes. Take a look:
    • "An alternatively translated isoform of PPARG proposes AF-1 domain inhibition as an insulin sensitization target." Diabetes 2025. PDF.
  • January 2025: Our work to profile plasma metabolites from patients with type 2 diabetes has been published in Diabetes Care. Check it out:
    • "Plasma Lipid Metabolites, Clinical Glycemic Predictors, and Incident Type 2 Diabetes." Diabetes Care 2025. PDF.
  • January 2025: Welcome AI expert and Bioinformatician Achint Kumar and Undergraduate Researcher Danielle Dang! Achint and Danielle are both interested in using AI to improve clinical decision-making and will work together with graduate student Emily on our new insulin-dosing project: aiDose.